

PRESENTATIONS AT NATIONAL OR INTERNATIONAL CONFERENCES

Dr CJ CLEMENTS

As Assistant Director, Department of Health, Wellington, New Zealand:

1. Joseph JG, Clements CJ. Sudden Infant Death Syndrome (SIDS) in Wellington; ANZSERCH Annual Conference, Christchurch Medical School, 1982.
2. The Child Health Report - Getting Off to a Good Start. At: Association for the Study of Childhood, Wellington, 9 April 1983.
3. The Child Health Report - What we should be doing about it? At: Royal Society of New Zealand, Wellington, 17 August 1983.
4. Leprosy control in New Zealand. At: *Department of Health Seminar on Leprosy in New Zealand*. Auckland, April 1983.
5. Health Education for Rheumatic Fever. At: *National Conference on Rheumatic Fever*. Auckland Medical School, New Zealand. May 1983.
6. Marshall RB, Clements CJ. Thermophilic Campylobacter infections of man and animals. At: *9th International Congress of Agricultural Medicine and Rural Health*. Otago University, Christchurch, New Zealand, 10 September 1984.
7. The Epidemiology of AIDS. At: *National Conference of the Society of Pathologists*. Auckland Medical School, New Zealand. 10 May 1985.

As Medical Officer, Expanded Programme on Immunization, WHO, Geneva:

8. The acceptability of children's vaccinations. At: *International Seminar on the acceptability of children's vaccines*. International Children's Center, 24 February 1986, Paris.
9. The global impact of the Expanded Programme on Immunization. At: A WHO consultation on HIV and routine childhood immunization, Geneva, 12-13 August 1987.
10. HIV infection and routine childhood immunization. At: WHO consultation on HIV infection and routine childhood immunization. Geneva, 12-13 August 1987.
11. Key issues in measles research. At: EPI/WHO Global Advisory Group Meeting, Washington, 4-7 November 1987.
12. WHO Global immunization policy. At: Hellenic National Conference on Vaccines. Athens, Greece, 28-29 November 1987.
13. Update on research into HIV infection and routine childhood immunization. At: EPI Research and Development Group Meeting, WHO Geneva, March 1988.
14. Successful strategies in immunization programmes. At: British Paediatric Association Conference, York, UK. 14 April 1988.

15. EPI overview. At: Medicus Mundi Training Course on Tropical Diseases, Brescia, Italy. September 1988.
16. The global situation concerning measles. At: Meeting on Alternative Measles Vaccines. Pan American Health Organization, Washington, 19-20 September 1988.
17. Progress in research into HIV infection and routine childhood immunization. At: WHO/EPI Research and Development Group Meeting, Abidjan, Cote d'Ivoire, October 1988.
18. Measles immunization before the age of nine months. At: WHO/EPI Global Advisory Group Meeting, Abidjan, Cote d'Ivoire, 17-21 October 1988.
19. Problems raised for the childhood immunization programme by HIV infection. At: XII International Congress for Tropical Medicine and Malaria, Amsterdam, 18-23 September 1988.
20. EPI - now and in the year 2000. At: Swedish Medical Association Conference on Health for developing countries, Stockholm, 27-28 October 1988.
21. Programme implications of the alternative measles vaccines for delivery of vitamin A in the Expanded Programme on Immunization. At: Vitamin A supplementation through the EPI. 26-27 January 1989. An IVAG meeting, WHO Geneva.
22. The limitations of present measles vaccines for the Expanded Programme on Immunization. At: Scientific Advisory Group of Experts Programme for Vaccine Development and Transdisease Vaccinology. WHO, Geneva, 10-12 July 1989.
23. Overview of the Expanded Programme on Immunization. At: Medicus Mundi Training Course on Tropical Diseases, Brescia, Italy. September 1989.
24. Summary of EPI Research and Development March to October 1989. At: Research and Development Group Meeting, Tokyo October 1989.
26. Overview of the Expanded Programme on Immunization. At: National Conference on Immunization, Melbourne, Australia. 13 November 1989.
27. Summary of EPI Research and Development October 1989 to March 1990. At: Research and Development Group Meeting, Geneva, 15-16 March 1990.
28. Hegggenhougen HK, Clements CJ. An anthropological perspective on the acceptability of immunization services. At: Workshop on neglected vaccines for developing countries, Bergen, 7-9 December 1989.
29. EPI requirements for a measles vaccine of the future. At: WHO Meeting on the development of new vaccines against measles. Rolle, Switzerland, 26-27 May 1990.
30. Control of measles in the 1990's. At: Workshop for managers of the Expanded Programme on Immunization, WHO/WPRO, Manila, 18-22 June 1990.
31. Control of measles in the 1990's. At: EPI Global Advisory Group Meeting, Cairo, Egypt, 14-18 October 1990.
32. Linked administration of measles vaccine and vitamin A supplementation. At: Joint WHO/UNICEF

Meeting on Micronutrient supplementation including the use of the Expanded Programme on Immunization. WHO, Geneva, 29 January 1991.

33. The challenge of Hepatitis B Vaccine for the Expanded Programme on Immunization. At: the International Conference on the Control of Hepatitis B in the Developing World. Yaoundé, Cameroon, 5-7 October 1991.

34. The Expanded Programme on Immunization in the 1990's. At: Second National Immunization Conference. Canberra, Australia. 27-29 May 1991.

35. Immunization today. At: The National Science and Technology Center, Canberra, Australia. 29 May 1991.

36. Surveillance sur la rougeole. Seminaire-atelier interpays sur la surveillance epidemiologique des maladies/cibles de Programme Elargi de Vaccination. Casablanca, 29 juillet - 1 aoute 1991.

37. Update of measles vaccine trials using AIKC and CAM/70 strains before nine months of age. At: EPI Research and Development Group Meeting, WHO Geneva, 1/2 October 1991.

38. Bolotovskiy VM, Grabowsky M, Albrecht P, Brenner ER, Clements CJ, Mikheyeva I, Titova NS, Zargaryonts AT. Seroresponse and adverse reactions in 6 an 9 month olds immunized with AIKC, EZ, L-16 and Schwarz measles vaccines. At: 31st Interscience Conference on Anitmicrobial Agents (ICAAC), Chicago, USA, 29 September - 2 October 1991.

39. Measles vaccine before nine months. At: the Second Asia Pacific Congress of Medical Virology. Bangkok, Thailand, 17-22 November 1991.

40. WHO's experience with global measles control. At: World Conference on Poliomyelitis and Measles: Vaccines and Immunization. New Delhi, India, 7-12 January 1992.

41. The loss of high titer measles vaccine - implications for research and policy for EPI. At: Consultation on studies involving high titer measles vaccines before nine months of age. President Carter Center, Atlanta, Georgia, USA. 16-27 June 1992.

42. Bolotovskiy VM, Grabowsky M, Albrecht P, Brenner ER, Clements CJ, Mikheyeva I, Titova NS, Zargaryonts AT. Serologic response to two Edmonston Zagreb Measles Vaccines in 6 month old infants. At: 32nd Interscience Conference on Anitmicrobial Agents (ICAAC), USA, 29 September - 2 October 1992.

43. Measles control in the Eastern Mediterranean. At: WHO/EPI Programme Managers' Meeting, EMRO. Cairo, Egypt, February 4-7, 1992.

44. Measles control in Africa. At: WHO/EPI Programme Managers' Meeting, African Region. Entebbe, Uganda, March 30 - April 4 1992.

45. Rosenthal S, Grabowsky M, Clements CJ. Two dose measles immunization schedules. At: EPI Research and Development Group Meeting, Geneva. 30 April - 1 May 1992.

46. Dias-Ortega JL, Forsey T, Clements CJ. The relationship between dose and response of standard measles vaccines: a review. At: EPI Research and Development Group Meeting, Geneva, 30 April - 1 May 1992.

47. The death of high titer measles vaccines. At: Ninth session of the Scientific Advisory Group of Experts (SAGE). 24-26 June 1992. WHO Geneva.
48. Measles – the global situation. At: Measles research needs. National Institutes of Health, Bethesda, Maryland, USA. 14/15 September 1992.
49. Two dose measles schedules. At: EPI Research and Development Group. Indonesia, Jakarta. 8/9 October 1992.
50. Safety of high titre measles vaccines. At: EPI Research and Development Group. Indonesia, Jakarta. 8/9 October 1992.
51. Global measles control. At: EPI Global Advisory Group Meeting. Jakarta, Indonesia. 12/16 October 1992.
52. Global measles control. At: 9th Inter-country programme managers' meeting, SEARO/WHO, Jakarta, Indonesia. 17/21 October 1992.
53. Estimation of measles mortality. At: WHO/UNICEF Consultation on the measurement of overall and cause-specific mortality in infants and children. WHO, Geneva. 15-17 December 1993.
54. Measles control strategies for investment. At: Ad hoc committee on an investment strategy for measles control. Children's Vaccine Initiative. Rockefeller Foundation Conference Center, Bellagio, Italy. 16-18 March 1993.
55. Elimination of measles in the Arabian Peninsula. At: Inter-country Sub-Regional (Gulf) Meeting of EPI Programme Managers. Muscat, Oman. 13-15 April 1993.
56. Treatment issues for measles case management. At: 10th Intercountry Meeting for WHO/EMR and UNICEF/MENAR. Cairo, 23-27 May 1993.
58. High risk approach to measles control. At: 10th Intercountry Meeting for WHO/EMR and UNICEF/MENAR. Cairo, 23-27 May 1993.
59. Improving measles control in South East Asia. At: Workshop on assessment and implementation of EPI plans. SEARO, Delhi, India. 24-28 May 1993.
60. Reaching the 1995 global measles control goals. At: EPI/WHO Global Advisory Group Meeting. Washington, USA, October 1993.
61. The revised plan of action for global measles control. At: EPI/WHO Global Advisory Group Meeting. Washington, USA, October 1993.
62. The need for clinical research in global measles control. At: Joint CDR/EPI Clinical Research Consultation on treatment of measles. 3-5 November 1993, MRC Unit, Banjul, Gambia.
63. The need for a new measles vaccine. At: A meeting on strategic issues in measles research at the Commission of European Community. Brussels, Belgium, 18 November 1993.
64. Booster doses (moderator of session). At: Fourth International Symposium on Immunization in Africa.

Yamoussoukro, Cote d'Ivoire. 14-16 March 1994.

65. Measles control in the urban African situation. At: EPI Programme Managers' Meeting for West Africa. Yamoussoukro, Cote d'Ivoire. 17-19 March 1994.

66. Strategies to meet the mid-decade measles control goals. At: GPV/CVI Informal Consultation on Strategies to Accelerate Global Measles Control. PAHO, Washington, USA. 27-28 April 1994.

67. Measles outbreak response. At: Eleventh Intercountry Meeting for National EPI Managers. WHO/EMR and UNICEF/MENAR. Tunis, Tunisia, 20-24 June 1994.

68. Development of a measles diagnostic test. At: WHO Task Force on Measles Vaccine Development. Geneva, 19 September 1994.

69. The need for development of alternative routes of administration of measles vaccines. At: WHO Task Force on Measles Vaccine Development. Geneva, 19 September 1994.

70. Review of measles control. At: Scientific Advisory Group of Experts, Global Programme for Vaccines and Immunization, Geneva, 17-19 October 1994.

71. Current status of WHO project in developing a network of laboratories for measles diagnosis. At: WHO/GPV Meeting on simple tests for laboratory diagnosis of measles infection. WHO, Geneva, 22 November 1994.

72. Measuring the impact of measles in Chad. At: A Meeting on Epidemiology and Field Research, WHO, Geneva, 20 October 1994.

73. The potential for incorporating existing measles vaccines into EPI for use at ages before 9 months of age. At: WHO Informal Consultation on the use of AIK-C strain of measles vaccine before nine months of age. Geneva, 22-23 May 1995.

74. Development of an aerosolized measles vaccine for mass campaigns. At: GPV/CVI Working Group for Research, Development and Introduction of Measles Vaccines and Diagnostic Tests. WHO, Geneva, 26-27 June 1995.

75. Technical requirements for rapid diagnostic tests to be used in EPI. At: GPV/CVI Working Group for Research, Development and Introduction of Measles Vaccines and Diagnostic Tests. WHO, Geneva, 26-27 June 1995.

76. Crohn's disease and measles. At: Scientific Advisor Group of Experts (SAGE). Geneva, 14-16 June 1995.

77. Does vitamin A reduce seroconversion to measles vaccine in infants? At: GPV Sub-Committee on EPI of the Scientific Advisor Group of Experts (SAGE). Geneva, 14-16 June 1995.

78. Measles: prospects for elimination and eradication. At: 19th International Congress of Chemotherapy, July 16-21, 1995, Montreal, Canada.

79. History of global strategies of immunization. At: Vaccinia, Vaccination, Vaccinology: Jenner, Pasteur and their successors. International Meeting on the History of Vaccinology. Marnes-la-Coquette, Paris, France. December 6-8 1995.

80. Problems impeding the development of an aerosolized measles vaccine. WHO Steering Committee on measles (ARV)-poliomyelitis vaccines. 25-26 March 1996. WHO, Geneva.
81. Using World Health Day 1996 to immunize the urban poor against measles. At: The opening ceremony of the 1996 World Health Day Celebrations. WHO Geneva, 15 April 1996.
82. Global immunization - can we sustain it in the 21st century? At: A symposium to celebrate the Jenner Bicentennial. Royal Society of Medicine, London, 16 May 1996.
83. Jenner - A Founding Father of Vaccines. (The 200th anniversary of Edward Jenner). At: The World Health Assembly, United Nations, Geneva, 22 May 1996.
84. Vaccine-preventable disease control. At: International Diploma Course in Health Emergency Preparedness and Crisis Management. 2 June - 2 July 1996, Geneva.
85. Immunization schedules and contraindications to immunization. At: Workshop on adverse events following immunization. 3-4 September 1996, Almaty, Kazakhstan.
86. The epidemiology of measles, mumps and rubella. At: Adolescent Health 2000 - Access through immunization. Monaco, 18-20 September 1996.
87. Rapid communication in the global polio laboratory network. At: Second Informal Consultation on the WHO Polio Laboratory Network. WHO Geneva, 2-4 October 1996.
88. The Expanded Programme on Immunization's response to emergencies. Co-ordinating Committee of the International Federation of Red Cross, Geneva, 21 November 1996.
89. Vaccine controversies in measles: is there a need for a new measles vaccine? At: 45th Annual Scientific Meeting of the American Society of Tropical Medicine and Hygiene, Baltimore, USA, 1-5 December 1996.
90. Current status of evaluating the feasibility of dry powder measles vaccine. At: WHO Informal consultation on alternative routes for administration of measles vaccine. Geneva, 24-25 March 1997.
91. Cutts FT, Clements CJ, Bennett JV. Alternative routes of measles immunization. At: WHO Informal consultation on alternative routes for the administration of measles vaccine. Geneva, 24-25 March 1997.
92. Strategies for elimination of vitamin A deficiency using immunization services. SAGE, Geneva, 11-13 June 1997.
93. Vitamin A with immunization services. WHO/UNICEF Meeting of African Anglophone Nutrition Programme Managers, Gaborone, Botswana 7-10 October 1997
94. WHO's position on the use of BCG. At: BCG Consultation, Ministry of Health, Cape Town, South Africa. 26-27 January 1998.
95. Research needs for vitamin A and immunization. GPV Research and Development Steering Committee on Epidemiology and Field Research. WHO, Geneva. 4-5 May 1998.
96. What contributions can social sciences make to the Expanded Programme on Immunization? At:

Social Science and Immunization Research Project. Woudschoten, The Netherlands. 25-29 May 1998.

97. To what extent are vaccine adverse events a deterrent to immunization? At: GPV Scientific Advisory Group of Experts. WHO Geneva, 9-11 June 1998.
98. Strategy to accelerate progress in the elimination of vitamin A deficiency as a public health problem. CCH(98)/5. WHO/UNICEF/UNFPA Co-ordinating Committee on Health (CCH) First meeting Geneva, 3-4 July 1998.
99. Expanding public confidence in vaccination: responding to questions of vaccine safety. (Presenter and co-facilitator). At: Children's Vaccine Initiative Consultative Group, The International Conference Centre, Geneva, Switzerland, 9-10 November 1998.
100. Esparza J, Clements CJ, Aguado T. HIV vaccines for developing countries: vaccination against the leading infectious killers of children. Organized by the Harvard AIDS Institute with co-sponsorship of UNAIDS. Dakar, Senegal 6-9 December 1998.
101. A new climate for vaccines and adverse events. At: Intercountry workshop on post-marketing surveillance including adverse events following immunization. Muscat, Oman, 20-22 February 1999.
102. Dalmiya N, Clements CJ, de Benoist B, Goodman T, Alnwick D, Sakai S, Zucker J. Policy into practice: linking vitamin A supplementation to national immunization days (NIDs). At: IVACG Meeting, 8-12 March 1999. Durban, South Africa.
103. Clements CJ. Recent developments concerning the scientific issues of combining vitamin A distribution with immunization programmes. (Presenter and chair of session). At: IVACG Meeting, 8-12 March 1999. Durban, South Africa.
104. The safety of vaccines – a global concern. At: The societal value of vaccination. European Vaccine Manufacturers, Brighton, UK. 17-19 March 1999.
105. Global perspectives on vaccine preservatives. At: *National Vaccine Advisory Committee-sponsored Workshop on Thiomersal in Vaccines*. 11-12 August 1999. Lister Hill Auditorium, National Institutes of Health, Bethesda, Maryland, US.
106. Global situation - measles control. At: *Intercountry workshop on measles elimination*. Muscat. Oman. 4-6 September 1999.
107. Adverse events following immunization. At *Workshop on partnership building with the media*. Muscat, Oman. 6-8 September 1999.
108. Adverse events following immunization. At Workshop on partnership building with the media. Islamabad. 27-29 September 1999.
109. Clements CJ. Vitamin A and polio eradication. At: Nutrition for health and development: review and planning exercise for 2000-2005. WHO Geneva, 22-24 September 1999.
110. Jodar L, Clements CJ. Vaccine adverse events and immunization programmes: A WHO perspective. At: World Vaccine Congress. Geneva 27-28 September 1999.

111. Thiomersal in modern vaccines. At: WHO Expert Committee on Biological Standardization. 25-29 October 1999. Geneva.
112. Media training. At: WHO Immunization Safety Steering Committee. 25-26 October 1999. Geneva.
113. Media training workshop. At: V&B Assessment and Monitoring Meeting. WHO Geneva, 27-28 October 1999.
114. Media training workshop. At: V&B Strategic Advisory Group Meeting (SAGE). WHO, Geneva, 1-3 November 1999.
115. Global overview of vaccine safety issues. At: WHO Global Training Network (GTN) "*A workshop on the national management of adverse events following immunization*". Cape Town, South Africa, 23 November- 3 December 1999.
116. Vaccine safety. At: Vaccines, victories & promises: a press briefing on vaccines and vaccine policy for Central and Eastern Europe and Middle East. 25-26 January 2000, Brussels, Belgium.
117. Clements CJ. Some risk benefit issues related to the introduction of children's vaccines. At: Future direction for rotavirus vaccine research in developing countries 9-11 February 2000, WHO, Geneva, Switzerland.
118. Adjuvants in vaccines - a global perspective. At: Workshop on Aluminium in Vaccines. National Vaccine Program Office, 11-12 May 2000, San Juan, Puerto Rico.
119. Clements CJ, Wikler D. Is it time for WHO to promote national vaccine compensation in developing countries? At: Vaccine Injury Compensation Meeting, Washington, 17-18 May 2000.
120. Aluminium as an adjuvant. At: Global Vaccine Safety Advisory Committee. WHO, Geneva. 5-6 June 2000.
121. Safety of thiomersal as a vaccine preservative. At: Scientific Review of Vaccine Safety Datalink Information. Centers for Disease Control (CDC), 7-8 June 2000, Simpsonwood Retreat Center, Atlanta, Georgia.
122. Recommendations for measles mass immunization. At Ministry of Health, Tirana, Albania. 30 June 2000.
123. Vaccine safety from a WHO perspective. 8th Meeting of the European Society of Pharmacovigilance. Verona, Italy, 21-23 September 2000.
124. WHO's experience in vaccine safety, adverse events and vaccine compliance. At: European Vaccine Symposium, Barcelona, Spain, 27-29 September 2000.
125. Strengthening immunization service management (Chair). Vaccines and Biologicals, WHO. Centre International de Geneva, 20 September 2000.
126. Global strategies for measles control and elimination. At: WHO Eastern Mediterranean Regional Intercountry Meeting on acceleration of measles control and elimination, 26-28 September 2000. Damascus, Syria.

127. Duclos P, Clements J. Thiomersal: a debated vaccine preservative. At: Pan American Health Organization Technical Advisory Group on Vaccine Preventable Diseases. XIV Meeting, 2-5 October 2000, Foz do Iguaçu, Parna, Brazil. PAHO, Washington, 2000.
128. Clements CJ, Duclos P. Crisis management and communication. At: 23rd Annual Meeting of the WHO Drug Monitoring Programme, Tunis, 12-14 November 2000.
129. Clements CJ. Thiomersal in vaccines. At: Global Vaccine Safety Advisory Committee. WHO, Geneva, 20-21 December 2000.
130. Clements CJ. The media and vaccines. At: WHO's Global Training Network Workshop "*A workshop on the national management of adverse events following immunization*". Dakar, Senegal, 12-17 March 2001.
131. Clements CJ. The strategic use of epidemiology in WHO's vaccine programmes (Keynote address). At: 19th Annual Meeting of the European Society for Paediatrics Infectious Diseases (ESPID). Istanbul, Turkey, 26-28 March 2001.
132. Clements CJ. (Author, organizer and presenter) The media and vaccines. At: WHO's Global Training Network Workshop "*A workshop on the national management of adverse events following immunization*". Santiago, Chile May 28-30 2001.
133. Clements CJ. The current WHO BCG immunization programme. At: Global forum on TB vaccines and development. WHO, Geneva, 7-8 June 2001.
134. Clements CJ. Research in progress to reduce or eliminate thiomersal from vaccines. At: Global Advisory Committee for Vaccine Safety. WHO, Geneva, 18-19 June 2001.
135. Clements CJ. Why BCG should be kept in the infant immunization schedule. At: WHO Strategic Group of Experts. Geneva, 14-15 June 2001.
136. Dellepiane N, Griffiths E, Clements CJ. Thiomersal in vaccines. At: WHO Strategic Group of Experts. Geneva, 14-15 June 2001.
137. Clements CJ. Global advocacy for immunization safety. At: Advocacy Task Force of the Global Alliance on Vaccines and Immunization (GAVI). The Bill and Melinda Gates Foundation. Seattle. 9-10 August 2001.
138. Clements CJ. (Author, organizer and presenter). The media and vaccines. At: WHO Global Training Network Workshop "*A workshop on the national management of adverse events following immunization*". Nepal November 2001.
139. Clements CJ. Update on the global situation regarding health effects of thiomersal in vaccines. At: *Global Advisory Committee on Vaccine Safety*. WHO, Geneva, 5-6 December 2001.
140. Clements CJ. The safety of infant vaccines in individuals who are HIV-infected. At: *Global Advisory Committee on Vaccine Safety*. WHO, Geneva, 5-6 December 2001.
141. Clements CJ. A global perspective on vaccine safety. At: *Course on systematic reviews of evidence of safety and effectiveness of EPI vaccines*. Alessandria, Italy, 14-18 January 2002.

142. Clements CJ. Mised and confused? The safety of vaccines. At: *Confidentiality and consent - where are the limits?* The Academy of Science, London, UK, 12-13 February 2002.
143. Clements CJ, Johnson P. Evaluating the role of BCG in the prevention of Buruli Ulcer. At: 5th WHO ad hoc group meeting on Buruli Ulcer. 11-14 March 2002, International Conference Center, Geneva.
144. Clements CJ. Delivery of preventive health services. At: *Global Consultation on Child and Adolescent Health and Development*. Stockholm, Sweden. 12-13 March 2002.
145. Clements CJ. The impact of a global immunization programme. At: *Symposium on vaccines*. European Parliament, Brussels, Belgium. 5 April 2002.
146. Clements CJ. Global overview of thiomersal and vaccines. At: *WHO Informal consultation on the impact of thiomersal on quality, safety and efficacy of vaccines: regulatory perspective*. 15-16 April 2002. WHO, Geneva, Switzerland.
147. Clements CJ. Implications of recent developments in thiomersal as a vaccine preservative for new vaccine introduction. At: *Accelerated Vaccine Introduction Priority Project Review*. WHO Geneva, 7-8 May 2002.
148. Clements CJ. Safety of injection devices. At: *First International Symposium on the Evaluation of Safety of Human Vaccines*. Rome, Italy, 22-23 May 2002.
149. Dellepiane N, Clements CJ, Bentsi-Enchill A, Griffiths E, Milstien J, Knezevic I. Thiomersal. At: The Strategic Group of Experts (SAGE). World Health Organization, Geneva, Switzerland, 13-14 June 2002.
150. Clements CJ. (Author, organizer and presenter) The media and vaccines. At: WHO's Global Training Network Workshop "A workshop on the national management of adverse events following immunization". Tunis, Tunisia, 15-20 July 2002.
151. Clements CJ. Vaccine safety and public opinion. At: *Pharmacy and Pharmaceutical Sciences World Congress 2002*. Nice, France. 31 August - 5 September 2002.
152. Clements CJ. Vaccination: current status of tuberculosis. At: *The immune system in protection and susceptibility to tuberculosis*. Scuola Superiore D'Immunologia, Ruggero, Ceppellini, Castello di Baia, Bacoli, Napoli, Italy. September 12-15 2002.
153. Bentsi-Enchill A, Clements CJ, Duclos P, Fitzner J, Folb P, Mehta U. Vaccines and Immunization Safety. At: *5th International Congress of Tropical Pediatrics*. 29 September 2002, Ankara, Turkey.
154. Clements CJ. Communicating with the media. At: *Consultation on developing communication strategies for immunization*. Tbilisi, Georgia. November 13-15, 2002.
155. State of the World's Vaccines and Immunization. At: International Press Launch of "State of the World's Vaccines and Immunization", UNICEF, New York, 19 November 2002.
156. Clements CJ. Clinical development strategies for children's vaccines - a retrospective look. At: *The ethics of performing vaccine trials in paediatric populations in high disease burden in developing countries*. Accra, Ghana. November 2002.

157. Adwoa Bentsi-Enchill, John Clements, Philippe Duclos, Julia Fitzner, Peter Folb, Ushma Mehta. Vaccines and Immunization Safety. At: 6th International Congress of Tropical Paediatrics – Ankara, Turkey. September 29 2002.
158. Clements CJ, Nkowane B. Issues related to the delivery of a new HIV vaccine. At: *WHO/UNAIDS/CDC Consultation on Public Health use of a first generation HIV vaccine: implementation issues related to different levels of efficacy*. A joint consultation of WHO, the United Nations Programme on HIV/AIDS (UNAIDS) and the US Centers for Disease Control and Prevention (CDC). Geneva, Switzerland. 20-21 November, 2002.
159. Clements CJ. Handling a crisis. At: UNICEF consultation on handling adverse events following vaccination. Sarajevo, Bosnia, 3-4 December 2003.
160. Clements CJ. HIV infection and immunization. At: Global Advisory Committee on Vaccine Safety Meeting. WHO, Geneva. 10 December 2002.
161. Clements CJ. Thiomersal and hepatitis B vaccine. At: Viral Hepatitis Prevention Board Meeting. Geneva, Switzerland, 13-14 March 2003.

As Associate Professor, Melbourne, Australia

162. Clements CJ. In-depth evaluation of PNG immunization services. At: In-service training. Women's and Children's Health Project, Port Moresby, Papua New Guinea, 6 May 2003.
163. Clements CJ. The use of epidemiological data for advocacy. At: Mekong Regional Immunization Forum for Senior Level Managers. Bangkok, Thailand 25-27 August 2003.
164. Clements CJ. How to handle negative rumours about vaccine safety. At: Mekong Regional Immunization Forum for Senior Level Managers. Bangkok, Thailand 25-27 August 2003.
165. Clements CJ. Reaching primary school children with vaccines. At: Sub-Regional Workshop on FRESH (Focusing Resources on Effective School Health). SEAMEO INNOTECH, Manila, Philippines. 17-21 November 2003.
166. Clements CJ. The impact of human papilloma virus vaccine on adolescent immunization. MICAHIG meeting, Children's Hospital, University of Melbourne, Melbourne. 21 January 2004.
167. Clements CJ. Progress in controlling hepatitis B in the Western Pacific Region, 2004. At: Technical Advisory Group Meeting, World Health Organization, Manila, 29-30 March 2004. Meeting Report: 14th Meeting of the Technical Advisory Group (TAG) on the EPI and Polio Eradication in the Western Pacific Region, 29-31 March 2004 (July 2004) http://www.wpro.who.int/NR/rdonlyres/90A3F38D-FC8E-48C3-BB04-841351AFCCFA/0/DOC_MTGRPT_TAG14.pdf.
168. Minn K, Morgan C, Clements CJ. Mekong Regional Immunization Training and Education (MRITE) Poster. At: World Conference on Health Promotion. Melbourne, 26-29 April 2004.
169. Clements CJ. Working with the media. At: World Conference on Health Promotion. Melbourne, 26-29 April 2004.

170. Clements CJ. Challenges for increasing and sustaining immunization coverage. At: World Conference on Health Promotion. Melbourne, 26-29 April 2004.
171. Clements CJ. The global immunization movement – its history, culture and politics. At: Medicine at the border. The history, culture and politics of global health. University of Sydney, 1-3 July 2004.
172. Clements CJ. (Poster). Winds of change for adolescent immunization - the human papillomavirus vaccine. At: Immunization at the crossroads– challenges and strategies. 9th National Immunization/1st Public Health Association of Australia Asia Pacific Vaccine Preventable Disease Conference. Cairns, Queensland, Australia, 19-20 August 2004.
173. Clements CJ. The Immunization Programme in the State of Jharkhand, India. At: The WHO review of the immunization programme in the six worst-performing states of India. New Delhi, 25 August – 10 September 2004.
174. Clements CJ. The Vaccine Independence Initiative in Pacific Island Countries; a vision for the future. At: WHO Second Pacific Immunization Programme Strengthening (PIPS) Workshop. Nadi, Fiji, 8-12 May 2006.
175. Clements CJ. An assessment of the hepatitis B programme in the Western Pacific. At: 10th National Immunization /2nd PHAA Pacific Vaccine Preventable Diseases Conference. Success in Immunization. 30 July-1 August 2006. Sydney Australia.
176. Wirkas T, Clements CJ. A freezing study of the cold chain in PNG. At: 10th National Immunization /2nd PHAA Pacific Vaccine Preventable Diseases Conference. Success in Immunization. 30 July-1 August 2006. Sydney Australia.
177. Morgan C, Hinton R, Aeno H, Kariwiga G, Auwun A, Posanai P, Toikilik S, Clements CJ, Duke T, Reeder J. (poster) Better use of public health campaigns for child survival. Rationale and methodology for operational research into PNG's Supplementary Immunisation Activity (SIA). Annual Scientific Medical Symposium. Madang, PNG. September 2006.
178. Clements CJ. Meeting summary. Local health managers in difficult environments. An AusAID-sponsored international meeting at the Burnet Institute, Melbourne, 17-19 April, 2007.
179. Toikilik S, Tuges G, Lagani J, et al. The national immunization coverage survey 2005. At: The Annual Medical Symposium. 3-7 September 2007. Port Moresby, Papua New Guinea.
180. Morgan CJ, Clements CJ. Strengthening the measurement of health program performance as a strategy for capacity development – a case study from immunisation in Papua New Guinea. At: World Vision Measuring Effectiveness Conference. Melbourne 2008. World Vision 2008 Measuring Effectiveness conference 25-26 September, Melbourne, Australia.
181. Clement Malau, Rohan Sweeney, Beverley Snell, Chris Morgan, Mike Toole, John C. Reeder, C. John Clements. Health Systems Development; can the local manager make the difference? At: Public Health Association of Australia National Conference, 7-9 July 2008. Brisbane, Australia.
182. Crawford N, Clements CJ. Mass psychogenic illness following vaccination: HPV and the role of SAFEVIC in response. At: 11th National Immunization Conference. 16-18 September 2008, Surfers Paradise, Australia.

183. Clements CJ. Thiomersal, autism and vaccine compensation. At: 11th National Immunization Conference. 16-18 September 2008, Surfers Paradise, Australia.
184. Michaela Riddell, Nicolas Senn, Doris Manong, Matthew Omena, Linda Hobday, Jonah Kurumbi, Ali Kevin, Peter Siba, John Clements, Chris Morgan. Rubella control in Papua New Guinea: use of age specific susceptibility to assess strategies for rubella vaccine introduction. At: Communicable Disease Control Conference 2009 (CDC 2009). 4-6 May 2009, Canberra, Australia.